Skip to main content

Table 3 ICU management and outcome data

From: Severe varicella-zoster virus pneumonia: a multicenter cohort study

Variables  
VZV-related treatment
 Aciclovir 102 (100%)
 Aciclovir dose, mg/8 h 10 (10–10)
 Steroids 10 (10%)
 Immunoglobulins 1 (1%)
 Systemic antibiotics at ICU admission 62 (61%)
Primary source of bacterial co-infection (n = 40, 39%)
 Lung 24 (60%)
 Bloodstream 8 (20%)
 Skin 4 (10%)
 Other 4 (10%)
Life-sustaining therapies
 Non-invasive mechanical ventilation 29 (28%)
 Invasive mechanical ventilation 52 (51%)
 Vasopressors 36 (35%)
 Renal replacement therapy 24 (24%)
ARDS criteria according to the Berlin definition (n = 42, 41%)
 Mild ARDS 8 (19%)
 Moderate ARDS 10 (24%)
 Severe ARDS 24 (57%)
Other interventions
 Neuromuscular blockers 26/52 (50%)
 Prone positioning 14/52 (28%)
 Veno-venous ECMO 7/52 (13%)
Outcome data
 ICU length of stay (days) 8 (4–16.75)
 Hospital length of stay (days) 14 (9–33)
 ICU mortality 17 (17%)
 Hospital mortality 24 (24%)
  1. Values are shown as n (%) or median (25th–75th percentiles)
  2. AKI acute kidney injury, ARDS acute respiratory distress syndrome, ECMO extra-corporeal lung oxygenation, ICU intensive care unit, VZV varicella-zoster virus